Amgen Inc. (NASDAQ:AMGN) Stock Holdings Trimmed by First Dallas Securities Inc.

First Dallas Securities Inc. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 9.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,257 shares of the medical research company’s stock after selling 732 shares during the quarter. First Dallas Securities Inc.’s holdings in Amgen were worth $1,891,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter valued at about $29,000. Matrix Trust Co bought a new position in shares of Amgen during the third quarter valued at approximately $36,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the fourth quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter valued at approximately $56,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $288.87 on Tuesday. The stock has a fifty day moving average of $271.06 and a 200-day moving average of $304.11. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market capitalization of $155.28 billion, a PE ratio of 36.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lowered their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Barclays upped their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Finally, Sanford C. Bernstein assumed coverage on Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective for the company. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.